T3 Pharmaceuticals AG Revenue and Competitors

Basel,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • T3 Pharmaceuticals AG's estimated annual revenue is currently $3.4M per year.(i)
  • T3 Pharmaceuticals AG's estimated revenue per employee is $155,000

Employee Data

  • T3 Pharmaceuticals AG has 22 Employees.(i)
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is T3 Pharmaceuticals AG?

Developing the next generation bacterial cancer therapy The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria. T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein delivery technology that is based on the use of live bacteria. While the technology has diverse applications in research, T3 Pharma has further developed the system to serve as a novel therapeutic to treat solid tumors.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

T3 Pharmaceuticals AG News

2022-04-06 - Compartmentalized metabolism supports midgestation mammalian ...

... one-way ANOVA followed by the Dunnett's T3 multiple-comparisons ... R.J.D. is an advisor for Agios Pharmaceuticals and Vida Ventures and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.2M22-31%N/A
#2
N/A2426%N/A
#3
N/A2735%N/A
#4
N/A2938%N/A
#5
$4.9M297%N/A